Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2024-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic low back pain (CLBP) is a prevalent condition causing significant pain, disability, and reduced quality of life. While various treatments like exercise, NSAIDs, and spinal manipulation are recommended, their effectiveness is limited. Epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks.

Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties. It has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. Using DXM in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine as an Intrathecal Adjuvant to Hyperbaric Bupivacaine for Postoperative Analgesia in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction Surgeries

NCT06667024

Dexmedetomidine Intrathecal Adjuvant +3 more

COMPLETED NA

Dexmedetomidine Versus Nalbuphine as an Adjuvant to Intrathecal Bupivacaine

NCT05347173

Analgesia

COMPLETED NA

Dexmedetomidine in Sonographic Guided Erector Spinae Plane Block

NCT06899841

Pain Management

RECRUITING PHASE2/PHASE3

Comparison of Different Doses of Dexmedetomidine Effect in the Duration of Spinal Anesthesia

NCT03143010

Spinal Anesthesia Duration

UNKNOWN NA

Optimal Single Dose Intrathecal Dexmedetomidine for Postoperative Analgesia

NCT02660658

Lower Limb Surgery

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine was injected in dose of 0.25 µg/kg

Intervention Type DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 0.5 µg/kg

Intervention Type DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 0.75 µg/kg

Intervention Type DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 1 µg/kg

Intervention Type DRUG

lidocaine and triamcinolone

2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks with manifest affection of daily activities;
* Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks with manifest affection of quality of walking and life;
* Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks maintained on systemic analgesics;

Exclusion Criteria

* The presence of osteolytic vertebral lesions;
* The Presence of previous surgical intervention;
* The presence of allergy to the studied drugs;
* Patients of ASA grade \>II.

Minimum Eligible Age

35 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No